Evidence map›Paper›PMID 40675820›Full record

ArticleGenes & development2025

A genome-wide, CRISPR-based screen reveals new requirements for translation initiation and ubiquitination in driving adipogenic fate change.

Rachel E Turn, Keren I Hilgendorf, Carl T Johnson, Kyuho Han, Mohammad Ovais Aziz-Zanjani, Samuel Swails Bollinger, Pablo Domizi, Ran Cheng, Atefeh Rabiee, Yingdi Zhu and 6 more

Abstract read
In one paragraph

Article in Genes & development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rachel E Turn *Baxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Keren I Hilgendorf *Baxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.ORCID 0000-0001-8377-8384
Carl T Johnson *Baxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Kyuho HanDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.
Mohammad Ovais Aziz-ZanjaniBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Samuel Swails BollingerBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Pablo DomiziDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplant, and Regenerative Medicine Program, Stanford University, Stanford 94305, California, USA.
Ran ChengBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Atefeh RabieeDepartment of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton 95211, California, USA.
Yingdi ZhuLaboratory of Physical and Analytical Electrochemistry (LEPA), Ecole Polytechnique Fédérale de Lausanne (EPFL) Valais Wallis, Sion 1950, Switzerland.
Zewen JiangDepartment of Pathology, Stanford University, Stanford, California 94305, USA.
Anushweta AsthanaBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Janos DemeterBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Katrin J SvenssonDepartment of Pathology, Stanford University, Stanford, California 94305, USA.ORCID 0000-0001-5376-5128
Michael C BassikDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.
Peter K JacksonBaxter Laboratory, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA; pjackson@stanford.edu.

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Training in Basic Research on Aging and Age-Related DiseaseT32AG000266 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Lisa M Ellerby · 1998 to 2026
$13.8M
Mechanisms controlling fructose uptake and utilizationR01DK125260 · NIDDK · STANFORD UNIVERSITY · PI Katrin Jennifer Svensson · 2020 to 2026
$3.5M
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancerU01CA199216 · NCI · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C, JACKSON, PETER KENT · 2015 to 2019
$3.2M
Accelerating drug development and repurposing using systematic genetic interactioDP2HD084069 · NICHD · STANFORD UNIVERSITY · PI BASSIK, MICHAEL C · 2014 to 2014
$2.4M
Centriolar-ciliary signaling mechanisms in tissue regeneration and differentiationR01GM114276 · NIGMS · STANFORD UNIVERSITY · PI JACKSON, PETER KENT · 2015 to 2018
$1.5M
The role of circulating Slit2 in adipose thermogenesis and diabetesR00DK111916 · NIDDK · STANFORD UNIVERSITY · PI SVENSSON, KATRIN JENNIFER · 2018 to 2020
$731k
TULP3 integrates essential ciliary functionsK99GM154060 · NIGMS · STANFORD UNIVERSITY · PI TURN, RACHEL ELIZABETH · 2024 to 2025
$250k
The role of circulating Slit2 in adipose thermogenesis and diabetesK99DK111916 · NIDDK · DANA-FARBER CANCER INST · PI SVENSSON, KATRIN JENNIFER · 2016 to 2017
$180k
The Role of eIF4G1 and eIF4G2 in Translational Control of Adipogenesis and ObesityF32GM142180 · NIGMS · STANFORD UNIVERSITY · PI TURN, RACHEL ELIZABETH · 2022 to 2023
$137k
NCI NIH HHS U01 CA199216NIA NIH HHS T32 AG000266NICHD NIH HHS DP2 HD084069NIDDK NIH HHS K99 DK111916NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R00 DK111916NIDDK NIH HHS R01 DK125260NIGMS NIH HHS F32 GM142180NIGMS NIH HHS K99 GM154060NIGMS NIH HHS R01 GM114276NIGMS NIH HHS T32 GM007276
6 · The paper itself

Abstract

In response to excess nutrients, white adipose tissue expands by both generating new adipocytes and upregulating lipogenesis in existing adipocytes. Here, we performed a genome-wide functional CRISPR screen to identify regulators of adipogenesis in the mouse 3T3-L1 preadipocyte model. In this pooled screening strategy, we used FACS to isolate populations based on lipid content, gating for fluorescence intensity of lipophilic fluorescent BODIPY dye. Additionally, we categorized whether the gene functions primarily during mitotic clonal expansion, lipogenesis, or both. We found that translation initiation and ubiquitin-dependent protein stability regulators drive both adipogenic fate change and lipogenesis. We further supported these findings with proteomics, demonstrating that essential changes in protein reprogramming can drive or inhibit 3T3-L1 adipogenesis independent of transcription. Furthermore, we demonstrated that specific branches of the hypusination pathway, a conserved regulator of translation initiation, are critical for translating adipogenic inducers of mitotic clonal expansion and that the neddylation/ubiquitin pathway modulates insulin sensitivity during lipogenesis.

Indexed as

AdipogenesisClustered Regularly Interspaced Short Palindromic RepeatsPeptide Chain Initiation, TranslationalUbiquitination3T3-L1 CellsAdipocytesAnimalsCRISPR-Cas SystemsLipogenesisMiceMitosisadipogenesisCRISPRhypusinelipidlipogenesismitotic expansionNedd8obesitytranslation initiationubiquitin-dependent proteolysis

Identifiers

PMID40675820
PMCPMC12487700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.